Personal information

Other IDs

SciProfiles: 1925437

Activities

Collapse all

Employment (1)

Zhejiang University School of Medicine First Affiliated Hospital: Hangzhou, Zhejiang, CN

2021-09-01 to 2024-06-30 | Resident (Hematology)
Employment
Source: Self-asserted source
Cheng Zu

Education and qualifications (1)

Zhejiang University School of Medicine: Hangzhou, Zhejiang, CN

2016-09-01 to 2021-06-30 | MBBS (Clinical Medicine)
Education
Source: Self-asserted source
Cheng Zu

Works (12)

Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis

New England Journal of Medicine
2024-04-25 | Journal article
DOI: 10.1056/NEJMoa2313812
Contributors: Yongxian Hu; Mingming Zhang; Tingting Yang; Zhuomao Mo; Guoqing Wei; Ruirui Jing; Houli Zhao; Rongrong Chen; Cheng Zu; Tianning Gu et al.
Source: check_circle
Crossref

A distinct cytokine network distinguishes chimeric antigen receptor T cell (CAR-T)–associated hemophagocytic lymphohistiocytosis-like toxicity (carHLH) from severe cytokine release syndrome following CAR-T therapy

Cytotherapy
2023-11 | Journal article
DOI: 10.1016/j.jcyt.2023.06.008
Contributors: Cheng Zu; Shenghao Wu; Mingming Zhang; Guoqing Wei; Huijun Xu; Jiazhen Cui; Alex H. Chang; He Huang; Yongxian Hu
Source: check_circle
Crossref

Cytokine release syndrome was an independent risk factor associated with hypoalbuminemia for patients with relapsed/refractory hematological malignancies after CAR-T cell therapy

BMC Cancer
2023-11-02 | Journal article
DOI: 10.1186/s12885-023-11540-8
Part of ISSN: 1471-2407
Contributors: Shuyi Ding; Rongrong Chen; Linqin Wang; Cheng Zu; Xiaoyu Zhou; Jianli Zhang; Mingming Zhang; Aiyun Jin; Tingting Wang; Yongxian Hu
Source: Self-asserted source
Cheng Zu

HBV reactivation in patients with chronic or resolved HBV infection following BCMA-targeted CAR-T cell therapy

Bone Marrow Transplantation
2023-06 | Journal article
DOI: 10.1038/s41409-023-01960-2
Contributors: Shan Fu; Qiqi Zhang; Ruirui Jing; Cheng Zu; Fang Ni; Yuqi Lv; Jiazhen Cui; Haiqiong Zheng; Yanlei Zhang; Mingming Zhang et al.
Source: check_circle
Crossref

Safety and efficacy of CRISPR-based non-viral PD1 locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory Non-Hodgkin's lymphoma: a first-in-human phase I study

eClinicalMedicine
2023-06 | Journal article
DOI: 10.1016/j.eclinm.2023.102010
Part of ISSN: 2589-5370
Contributors: Yongxian Hu; Cheng Zu; Mingming Zhang; Guoqing Wei; Wei Li; Shan Fu; Ruimin Hong; Linghui Zhou; Wenjun Wu; Jiazhen Cui et al.
Source: Self-asserted source
Cheng Zu

HLA Fully-Mismatched Sibling-Derived CD7 CAR-T Therapy Bridging to Haploidentical Hematopoietic Stem Cell Transplantation for Hepatosplenic γδ T-cell Lymphoma

Cell Transplantation
2023-01 | Journal article
DOI: 10.1177/09636897231194265
Part of ISSN: 0963-6897
Part of ISSN: 1555-3892
Contributors: Xueer Xu; Cheng Zu; Mingming Zhang; Pingnan Xiao; Ruimin Hong; Jingjing Feng; Huijun Xu; Jiazhen Cui; Jian Yu; Jimin Shi et al.
Source: Self-asserted source
Cheng Zu

Pomalidomide-based regimens bridging CAR-T therapy in multiple myeloma with central nervous system involvement

Regenerative Therapy
2022-12 | Journal article
DOI: 10.1016/j.reth.2022.05.007
Contributors: Qiqi Zhang; Cheng Zu; Fang Ni; Zhe Yang; Zhiye Zhang; Mingming Zhang; He Huang; Yongxian Hu
Source: check_circle
Crossref

Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study

Cell Research
2022-09-23 | Journal article
DOI: 10.1038/s41422-022-00721-y
Part of ISSN: 1748-7838
Contributors: Yongxian Hu; Yali Zhou; Mingming Zhang; Houli Zhao; Guoqing Wei; Wengang Ge; Qu Cui; Qitian Mu; Gong Chen; Lu Han et al.
Source: Self-asserted source
Cheng Zu

CAR-T cells for cancer immunotherapy—the barriers ahead and the paths through

International Reviews of Immunology
2022-05-28 | Journal article
DOI: 10.1080/08830185.2022.2080820
Part of ISSN: 0883-0185
Part of ISSN: 1563-5244
Source: Self-asserted source
Cheng Zu

BCMA CAR-T Therapy Is Safe and Effective for Refractory/Relapsed Multiple Myeloma With Central Nervous System Involvement

Journal of Immunotherapy
2022-01 | Journal article
DOI: 10.1097/cji.0000000000000391
Part of ISSN: 1524-9557
Source: Self-asserted source
Cheng Zu

Cytomegalovirus Retinitis and Retinal Detachment following Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory Multiple Myeloma

Current Oncology
2022-01-24 | Journal article
DOI: 10.3390/curroncol29020044
Part of ISSN: 1718-7729
Source: Self-asserted source
Cheng Zu
grade
Preferred source (of 3)‎

Successful BCMA CAR-T Therapy for Multiple Myeloma With Central Nervous System Involvement Manifesting as Cauda Equina Syndrome—A Wandering Road to Remission

Frontiers in Oncology
2021-11-17 | Journal article
DOI: 10.3389/fonc.2021.755584
Part of ISSN: 2234-943X
Source: Self-asserted source
Cheng Zu
How many people are using ORCID?